More from Dr. Quay in today's announcement - Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- #BreastCancer https://lnkd.in/eN6ebcws
Atossa Therapeutics, Inc.
Biotechnology
Seattle, WA 4,442 followers
Clinical-stage biopharmaceutical company developing novel, proprietary therapeutics for breast cancer and conditions.
About us
Atossa Genetics Inc. (NASDAQ: ATOS) is developing locally-administered pharmaceuticals for pre-cancerous breast conditions and early stage breast cancer.
- Website
-
http://www.atossagenetics.com
External link for Atossa Therapeutics, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Seattle, WA
- Type
- Public Company
- Founded
- 2009
- Specialties
- Molecular diagnostics, Breast cancer, and Breast cancer prevention
Locations
-
Primary
Get directions
1616 Eastlake Ave E, Suite 201
Seattle, WA 98102, US
Employees at Atossa Therapeutics, Inc.
-
Delly Behen, SHRM-CP, PHR
Experienced Human Resources Leader
-
Suzy Matter
Executive Administrator
-
Michael Parks
Global Communications Executive | Investor Relations and Public Affairs Leader | Issues Management Advisor
-
Lonnissa H. Nguyen, PhD, RAC
Executive Director, Head of Regulatory Affairs at Atossa Therapeutics
Updates
-
More in today's announcement: (Z)-endoxifen at 10mg once daily met primary endpoint with 19/20 (95%) receiving >75% of planned treatment in I-SPY-2 Ph 2 Trial Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 & FTV Biomarkers Read the full release below - $ATOS #breastcancer https://lnkd.in/eN6ebcws
-
Atossa Therapeutics, Inc. Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer #RiseUpforBreastCancer #BreastCancer #ClinicalTrials https://lnkd.in/eN6ebcws
BREAKING: Here is an Explainer video on the latest news from Atossa Therapeutics #ATOS. Just in time for #breastcancer awareness month.
iSPY Explainer Video
https://www.youtube.com/
-
Breaking news from Atossa $ATOS
BREAKING: Here is an Explainer video on the latest news from Atossa Therapeutics #ATOS. Just in time for #breastcancer awareness month.
iSPY Explainer Video
https://www.youtube.com/
-
A great way to end the month of October in the Big Apple.
Proud to be supporting #breastcancer awareness at $ATOS... until we achieve our aspiration of preventing breast cancer!
-
-
Together Atossa Therapeutics, Inc. & Nasdaq proudly support #BreastCancerAwareness. Thanks to all working to raise awareness as we strive to transform the #breastcancer paradigm. Learn more here. https://lnkd.in/emqfzFGi
-
-
Did you know: Every 2 minutes an American woman is diagnosed with #breastcancer. Learn more about the #BreastCancerProblem & our mission -to develop innovative medicines to transform the cancer paradigm #BreastCancerAwarenessMonth https://lnkd.in/esH32akW
-
-
Thanks to Jenna Fischer, NBC News & the Today Show for sharing your breast cancer diagnoses and treatment journey during #BreastCancerAwarenessMonth. An important part of Jenna’s story is #DenseBreast tissue – which can increase the risk of developing #breastcancer while making diagnosis difficult. Watch and share her story here. https://lnkd.in/eFarqRb5
Jenna Fischer recalls moment she learned about her breast cancer diagnosis
nbcnews.com
-
More from today's announcement - #breastcancer $ATOS https://lnkd.in/eRDdgd76
-
A very big announcement today
I am honored to join Dr. Hall of the Karolinska Institute at BIO-Europe 2024 and discuss the potential for AI and endoxifen to transform the breast cancer treatment paradigm by identifying women at high risk of developing breast cancer who could potentially benefit from treatment to prevent the disease before it develops. The focal point of the fireside chat will be the Stockholm Mammography Risk Stratified Trial or SMART study, which Dr. Hall’s laboratory is leading and Atossa is supporting. This groundbreaking study is seeking to enroll 70,000 women to test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model is validated for therapeutic use, it could serve as the foundation for a future trial investigating (Z)-endoxifen in the breast cancer prevention setting. #breastcancer #breastcancerprevention https://lnkd.in/gpKDrBnf
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer - Atossa Therapeutics
investors.atossatherapeutics.com